Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

CONTEXT: In the Women's Health Initiative estrogen plus progestin trial, after mean (SD) intervention of 5.6 (1.3) years (range 3.7 to 8.6 years) and mean follow-up of 7.9 (1.4) years, breast cancer incidence was increased by combined hormone therapy. However, breast cancer mortality results ha...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA
Asıl Yazarlar: Chlebowski, Rowan T., Anderson, Garnet L., Gass, Margery, Lane, Dorothy S., Aragaki, Aaron K., Kuller, Lewis H., Manson, JoAnn E., Stefanick, Marcia L., Ockene, Judith, Sarto, Gloria E., MD, Karen C. Johnson, Wactawski-Wende, Jean, Ravdin, Peter M., Schenken, Robert, Hendrix, Susan L., Rajkovic, Aleksandar, Rohan, Thomas E., Yasmeen, Shagufta, Prentice, Ross L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142300/
https://ncbi.nlm.nih.gov/pubmed/20959578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2010.1500
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller